Shots:

• The P-II cohort of the CodeBreaK 100 clinical study involves assessing Sotorasib (AMG 510- 960mg- qd) in 126 patients with KRAS G12C-mutated advanced NSCLC. The findings will be presented at the IASLC 2020 WCLC
• Results: @median follow up of 12.2 mos.- ORR (37.1%); DCR (80.6%); mDoR (10 mos.)- PFS (6.8 mos.). Median tumor shrinkage among all responders was 60% and complete responses observed
• Sotorasib is 1st KRAS G12C Inhibitor to enter the clinic and is being studied in the broadest clinical program exploring 10 combinations with global sites spanning five continents

 ­ Ref: PRNewswire | Image: Amgen